Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1
Pfizer has secured up to $1.5 billion from the investment group Blackstone Life Sciences to help pay for the development of its obesity candidate berobenatide. The co-funding agreement will see that cash come from funds ...
November 12, 2026 06:17 AM EST DealsR&D Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1 Elizabeth Cairns Senior biopharma journalist Pfizer has secured up to $1.5 billion from the investment group Blackstone Life Sciences to help pay for the development of its obesity candidate berobenatide. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that